Orthogon Therapeutics
Orthogon Therapeutics is a pioneering biotech company focused on drug discovery and development for viral infections, especially polyomaviruses. They leverage multiple technical innovations including 3D atomic mapping, compound libraries, and AI to develop novel therapeutics. Their mission is to impact future treatments by creating innovative drugs, with an initial focus on transplant patients and BK virus infections.
Industries
Nr. of Employees
small (1-50)
Orthogon Therapeutics
45 Dan Road Suite 126 Canton, MA 02021
Products
Orally administrable antiviral candidate(s) for polyomaviruses (preclinical pipeline)
A portfolio of orally administered small-molecule antiviral candidates developed to target polyomaviruses through novel mechanisms, including direct viral protein engagement and virus-specific host-target modulation.
Orally administrable antiviral candidate(s) for polyomaviruses (preclinical pipeline)
A portfolio of orally administered small-molecule antiviral candidates developed to target polyomaviruses through novel mechanisms, including direct viral protein engagement and virus-specific host-target modulation.
Services
Integrated discovery platform combining structural mapping, biophysical characterization, compound libraries, and machine learning to identify and optimize small-molecule candidates.
Integrated discovery platform combining structural mapping, biophysical characterization, compound libraries, and machine learning to identify and optimize small-molecule candidates.
Expertise Areas
- Antiviral drug discovery
- Structure-based drug design
- Biophysical assay development and interpretation
- Medicinal chemistry and lead optimization
Key Technologies
- Structure-based drug design
- Biophysical kinetics and thermodynamics assays
- Experimentally-directed machine learning/AI
- Privileged/target-enriched compound libraries